<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Chem.</journal-id>
<journal-title>Frontiers in Chemistry</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Chem.</abbrev-journal-title>
<issn pub-type="epub">2296-2646</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">753146</article-id>
<article-id pub-id-type="doi">10.3389/fchem.2021.753146</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Chemistry</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Decoding Conformational Imprint of Convoluted Molecular Interactions Between Prenylflavonoids and Aggregated Amyloid-Beta42 Peptide Causing Alzheimer&#x2019;s Disease</article-title>
<alt-title alt-title-type="left-running-head">Srinivasan et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">Computational Molecular Studies Against Amyloid-Beta42</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Srinivasan</surname>
<given-names>E.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1247943/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chandrasekhar</surname>
<given-names>G.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1435796/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chandrasekar</surname>
<given-names>P.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Anbarasu</surname>
<given-names>K.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vickram</surname>
<given-names>AS</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/597603/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tayubi</surname>
<given-names>Iftikhar Aslam</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rajasekaran</surname>
<given-names>R.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1432204/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Karunakaran</surname>
<given-names>Rohini</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1354511/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Bioinformatics Lab, Department of Biotechnology, School of Bio Sciences and Technology, Vellore Institute of Technology (Deemed to be University)</institution>, <addr-line>Vellore</addr-line>, <country>India</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Bioinformatics, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences</institution>, <addr-line>Chennai</addr-line>, <country>India</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences</institution>, <addr-line>Chennai</addr-line>, <country>India</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Faculty of Computing and Information Technology, King Abdulaziz University</institution>, <addr-line>Jeddah</addr-line>, <country>Saudi Arabia</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Unit of Biochemistry, Faculty of Medicine, AIMST University</institution>, <addr-line>Bedong</addr-line>, <country>Malaysia</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/203369/overview">Nino Russo</ext-link>, USniversity of Calabria, Italy</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/545920/overview">Adriana Pietropaolo</ext-link>, University of Catanzaro, Italy</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1418115/overview">Jannathul Firdous</ext-link>, University of Kuala Lumpur, Malaysia</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Rohini Karunakaran, <email>rohini@aimst.edu.my</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Theoretical and Computational Chemistry, a section of the journal Frontiers in Chemistry</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>20</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>9</volume>
<elocation-id>753146</elocation-id>
<history>
<date date-type="received">
<day>17</day>
<month>08</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>11</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Srinivasan, Chandrasekhar, Chandrasekar, Anbarasu, Vickram, Tayubi, Rajasekaran and Karunakaran.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Srinivasan, Chandrasekhar, Chandrasekar, Anbarasu, Vickram, Tayubi, Rajasekaran and Karunakaran</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>Protein misfolding occurs due to the loss of native protein structure and adopts an abnormal structure, wherein the misfolded proteins accumulate and form aggregates, which result in the formation of amyloid fibrils that are associated with neurodegenerative diseases. Amyloid beta (A&#x3b2;42) aggregation or amyloidosis is contemplated as a unique hallmark characteristic of Alzheimer&#x2019;s disease (AD). Due to aberrant accrual and aggregation of A&#x3b2;42 in extracellular space, the formation of senile plaques is found in AD patients. These senile plaques occur usually in the cognitive and memory region of the brain, enfeebles neurodegeneration, hinders the signaling between synapse, and disrupts neuronal functioning. In recent years, herbal compounds are identified and characterized for their potential as A&#x3b2;42 inhibitors. Thus, understanding their structure and molecular mechanics can provide an incredible finding in AD therapeutics. To describe the structure-based molecular studies in the rational designing of drugs against amyloid fibrils, we examined various herbal compounds that belong to prenylflavonoids. The present study characterizes the trends we identified at molecular docking studies and dynamics simulation where we observed stronger binding orientation of bavachalcone, bavachin, and neobavaisoflavone with the amyloid-beta (A&#x3b2;42) fibril structure. Hence, we could postulate that these herbal compounds could be potential inhibitors of A&#x3b2;42 fibrils; these anti-aggregation agents need to be considered in treating&#x20;AD.</p>
</abstract>
<kwd-group>
<kwd>alzheimer&#x2019;s</kwd>
<kwd>amyloid-beta</kwd>
<kwd>neobavaisoflavone</kwd>
<kwd>herbal active compounds</kwd>
<kwd>computational screening</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Alzheimer&#x2019;s disease (AD) is the archetypal impetus behind the mental deterioration of people over the age of 50, categorized as debilitative neurodegenerative disorder (<xref ref-type="bibr" rid="B14">Finder, 2010</xref>). Neuronal death, existence of neutrophil threads, specific loss of neurons, and synapse loss in the brain peculiarize AD. The essential key factors involved in the pathological prognosis of AD are the amyloid-beta (A&#x3b2;) peptide (rich in beta-sheet) constituted extracellular plaque formation, intracellular development of neurofibrillary tangles, and the degeneration of synapse (<xref ref-type="bibr" rid="B1">Al- Ayadhi et&#x20;al., 2012</xref>; <xref ref-type="bibr" rid="B15">Gouras et&#x20;al., 2015</xref>). Distinctly, beta-amyloid, an amyloid beta-peptide, is an aberrant protein that is increasingly noted for its protein misfolding activity in AD (<xref ref-type="bibr" rid="B36">Sarasa et&#x20;al., 2000</xref>; <xref ref-type="bibr" rid="B47">Sweeney et&#x20;al., 2017</xref>). In AD, amyloid beta-peptide 42 (A&#x3b2;42) is a well-known biomarker exhibiting the amyloidogenic activity that characterizes AD, due to the level of amyloid-beta deposits in cerebrospinal fluid. Secretases cleaves A&#x3b2; from large APP, thus producing the A&#x3b2;(1&#x2013;42) to wrap up as an amyloid plaque that causes synaptic damage and neuron loss in brain (<xref ref-type="bibr" rid="B28">Obregon et&#x20;al., 2012</xref>) (<xref ref-type="fig" rid="F1">Figure&#x20;1</xref>). A&#x3b2;42 is known to be more neurotoxic because of the additional two amino acid residues called long-tailed, which leads to protein misfolding. A&#x3b2;42 is a 4-kDa soluble peptide (<xref ref-type="bibr" rid="B29">Owen et&#x20;al., 1990</xref>; <xref ref-type="bibr" rid="B27">Murphy and LeVine, 2010</xref>), consisting of forty-two amino acids that resides inside the brain&#x2019;s cortex. In particular, A&#x3b2;42 constitutes the majority of intraneuronal A&#x3b2; (<xref ref-type="bibr" rid="B4">Chen et&#x20;al., 2017</xref>). These amyloid-beta oligomers form extracellular senile plaque deposits, protofibrils, and small oligomers with harmful effects such as synaptic damage, mitochondrial dysfunction, injury or dysfunction of neuronal cells, and death of neuronal cells that cause shrinkage and functional changes in the brain. This process is known as Amyloid cascade hypothesis, a hallmark in AD (<xref ref-type="bibr" rid="B32">Pimplikar, 2009</xref>; <xref ref-type="bibr" rid="B33">Reitz, 2012</xref>; <xref ref-type="bibr" rid="B35">Ricciarelli and Fedele, 2017</xref>). Specifically, the mutations such as KM670/671NL, A673T, A673V, D678H, E682K, K687N, A692G, and M722K increase the level of A&#x3b2;42 that leads to protein misfolding and accrual in AD. Typically, these aberrant proteins are supposed to be degraded by the ubiquitin (Ub)&#x2013;proteasome system (UPS) and chaperone-mediated autophagy (CMA) pathways; however, under obscure circumstances, amyloid eludes the proteolytic pathways and furthers its accumulation in neuronal cells (<xref ref-type="bibr" rid="B5">Ciechanover and Kwon, 2015</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Process involved in the production of amyloid beta plaques.</p>
</caption>
<graphic xlink:href="fchem-09-753146-g001.tif"/>
</fig>
<p>Small molecules are easy to administer, inexpensive to make, and can effectively traverse the blood&#x2013;brain barrier, more rapidly. Furthermore, studies have shown that naturally occurring polyphenolic compounds are known to effectively modulate pathological aggregates of various proteopathic proteins. Attributable to its functional group, polyphenols interact with neurotoxic amyloids to act as potent anti-aggregation agents (<xref ref-type="bibr" rid="B2">Freyssin et&#x20;al., 2018</xref>). Particularly, polyphenolic prenylflavonoid compounds from <italic>P. corylifoliaseeds</italic> were found to be neuroprotective in nature (<xref ref-type="bibr" rid="B20">Kim Y. et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B23">Lee et&#x20;al., 2016</xref>). Bavachalcone and bavachin regulate the amyloid-beta produced by BACE-1 enzyme (<xref ref-type="bibr" rid="B38">Shewmaker et&#x20;al., 2011</xref>). Neobavaisoflavone has remarkable anti-inflammatory properties (<xref ref-type="bibr" rid="B7">Colvin et&#x20;al., 2015</xref>). Lately, several computational studies have been carried out to efficiently observe, assess, and quantify the dynamic biomolecular interaction between therapeutic candidates (<xref ref-type="bibr" rid="B16">Gurevich and Gurevich, 2014</xref>; <xref ref-type="bibr" rid="B3">Bulfone et&#x20;al., 2018</xref>) and proteopathic targets like amyloids (<xref ref-type="bibr" rid="B41">Srinivasan and Rajasekaran, 2016</xref>, <xref ref-type="bibr" rid="B43">2017</xref>, <xref ref-type="bibr" rid="B40">2018a</xref>, <xref ref-type="bibr" rid="B44">2018b</xref>, <xref ref-type="bibr" rid="B42">2019</xref>; <xref ref-type="bibr" rid="B45">Srinivasan et&#x20;al., 2019</xref>).</p>
<p>Therefore, in the present study, these three herbal prenylflavonoids were evaluated computationally to investigate their anti-aggregation potency and binding efficacy with the help of quantum mechanics, molecular docking, and dynamic simulations.</p>
</sec>
<sec sec-type="methods" id="s2">
<title>Methodology</title>
<sec id="s2-1">
<title>Enhancement of the A&#x3b2;42 and Prenylflavonoids&#x2019; Structural Geometry</title>
<p>Initially, the structural coordinates of native A&#x3b2;42 (<xref ref-type="fig" rid="F2">Figure&#x20;2</xref>) were recovered from Protein Data Bank (PDB) (ID: 2BEG). To minimize the potential energy of the A&#x3b2;42 structural coordinates, GROningen MAchine for Chemical Simulations (GROMACS) with GROMOS 43a5 force field was employed (<xref ref-type="bibr" rid="B17">Hess et&#x20;al., 2008</xref>). The molecular system was solvated within a cubic box with SPCE water molecules where the counter ions were added for neutralizing the system. Periodic boundary condition (PBC) and PME (Particle Mesh Ewald) were included in the simulation (<xref ref-type="bibr" rid="B9">Darden, York, and Pedersen., 1993</xref>). Finally, Steepest Descent algorithm was used to optimize the structural coordinates of A&#x3b2;42.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>3D structure of amyloid-beta 42 fibrils.</p>
</caption>
<graphic xlink:href="fchem-09-753146-g002.tif"/>
</fig>
<p>Small-molecule inhibitors were procured from PubChem, a proficient database that contains an extensive collection of chemical molecules (<xref ref-type="bibr" rid="B19">Kim S. et&#x20;al., 2016</xref>). To optimize these structures, the def-SV(P) basis set containing TURBOMOLE&#x2019;s B-3LYP functional set for DFT optimization was utilized (<xref ref-type="bibr" rid="B46">Steffen et&#x20;al., 2010</xref>); these optimized structures were subjected to further analyses.</p>
</sec>
<sec id="s2-2">
<title>Molecular Docking Studies</title>
<p>Using Autodock 4.2.3 software (<xref ref-type="bibr" rid="B53">Morris et&#x20;al., 2009</xref>), docking simulation was performed, combining a fast energy assessment derived from pre-determined grids with separate search modules to find a suitable interaction location on the given protein for ligand. The structure being held tight during docking, the torsional bonds in small-molecule inhibitors were not restricted for flexible ligand docking. For docking calculations, we utilized the Lamarckian genetic algorithm with semi-empirical free energy and pre-computed grid maps. Using Auto Grid, we calculated the grid maps and used the default parameters to run the program. The grid maps were selected to encompass all amino acids with grid spacing between grid points set to 0.375&#xa0;&#xc5;. Using Lamarckian Genetic Algorithm, we executed molecular docking operation to produce 100 potential complexes (of protein and ligand) by presenting ligand orientation search on each ligand 100&#x20;times for the protein model. We conducted triplicates of the ligand conformation search for protein for each ligand to procure the most accurate findings. The interface between ligand and protein was tested independently, using free energy computations that are ascertained semi-empirically. Besides, free energy was measured by adding intermolecular (van der Waals, hydrogen bond, electrostatic, and desolvation) energy, internal energy, torsional energy, and total energy for flexible ligand binding with protein. Furthermore, we examined the optimal docked complex with least binding energies.</p>
</sec>
<sec id="s2-3">
<title>Ligand on Quantum Chemical Analysis</title>
<p>To be specific, we executed ligand quantum chemistry calculations, operating TURBOMOLE package DFT/B3LYP, raising single point energy measurement (<xref ref-type="bibr" rid="B46">Steffen et&#x20;al., 2010</xref>). On the ground state, the ligands&#x2019; 3D structure was optimized completely. Initially, the input geometry was optimized, using the def-SV(P) basis set through DFT/B3LYP with the B3-LYP functional set for essential atoms like C, O, N, and H combining three Becke&#x2019;s functional parameter exchange (B3) by Lee, Young, and Parr functional correlation (LYP).</p>
</sec>
<sec id="s2-4">
<title>Discrete Molecular Dynamics</title>
<p>Furthermore, we executed structural dynamics through the simulation of DMD (<xref ref-type="bibr" rid="B39">Shirvanyants et&#x20;al., 2012</xref>), the discrete molecular dynamics using distinct energy parameters computed with the discontinuous functions for calculating pairwise interaction; this study used the Atomistic Medusa DMD force field. Medusa force field is specifically parameterized for studying protein dynamics that effectively elucidates protein misfolding and illustrates conformational disturbances associated to mutations and other structural variations (<xref ref-type="bibr" rid="B10">Ding and Dokholyan, 2008</xref>). To elucidate a protein model exhibiting heavy atoms and polar hydrogen atoms, the united atom model was used. Covalent bonds, dihedrals, and bond angles comprise bonded interactions, while the environment-dependent H bonds, van der Waals, and solvation comprised bonded associations. The implicit Lazaridis&#x2013;Karplus solvation model was used as a reference state to ascertain the solvated energy of conformations. With reaction-like algorithms, hydrogen bond interactions were modeled. With Debye&#x2013;Huckel approximation, we modeled the screened charge&#x2013;charge interactions by setting Debye duration to approximately 10&#xa0;&#xc5;. Furthermore, distance restraints in between each metal atom and its commensurate metal-coordinating atoms were assigned for modeling the binding of metal ions, as stated from earlier studies. With a reaction algorithm, the distance and coordination dependency of the establishment of disulfide bonds were also modeled (<xref ref-type="bibr" rid="B10">Ding and Dokholyan, 2008</xref>). For performing DMD simulations, the volume and periodic boundary conditions were kept constant; we employed Anderson thermostat to regulate and maintain fixed temperature during simulation. Additionally, the configuration of the simulation system was snapshotted once in every 100&#x20;time units and the simulation was carried out for a time period of 1&#x20;&#xd7; 10<sup>5</sup> time&#x20;units.</p>
<p>Herein, DMD simulations signify the length [L] in Angstrom (10<sup>&#x2212;10</sup>&#xa0;m), the time unit [T] as determined by the mass units [M] in Dalton (1.66 &#xd7; 10<sup>&#x2212;24</sup>&#xa0;g), and energy [E] in kcal/mol (6.9 &#xd7; 10<sup>&#x2013;22</sup>&#xa0;J). With respect to classical MD, approximately 50 fs represents each time unit (<xref ref-type="bibr" rid="B10">Ding and Dokholyan, 2008</xref>). Finally, geometrical assessment on all the structural trajectories enumerated throughout the simulation were performed, using GROMACS such as Define Secondary Structure of Proteins (DSSP) (secondary structural propensity), g-rms (conformational deviation), g-gyrate (protein gyration), and g-rmsf (conformational flexibility).</p>
</sec>
<sec id="s2-5">
<title>Steered Molecular Dynamics</title>
<p>With Yet Another Scientific Artificial Reality Application (YASARA), SMD was carried out for bavachalcone, bavachin, and neobavaisoflavone attached to A&#x3b2;42 fibril and native A&#x3b2;42 fibril, keeping the temperature constant at 298&#xa0;K. Furthermore, we conducted the simulations employing AMBER03 force field (<xref ref-type="bibr" rid="B50">Wang et&#x20;al., 2004</xref>) in a solvation box of 0.997&#xa0;g&#xa0;ml<sup>&#x2212;1</sup>solvent density water molecules. In addition, we neutralized the system charge assigning 0.9% NaCl. Moreover, we maintained pH at 7.0 throughout the simulation. Together with periodic boundary conditions, long-range coulomb forces were added; thus, we assigned these parameters to perform energy minimization with steepest descent algorithm. In addition, we started the simulation by fixing the pulling acceleration to 1,000&#xa0;pm/ps<sup>2</sup> to independently extract bavachalcone, bavachin, and neobavaisoflavone compounds from the native complex, because the software uses constant acceleration to conduct SMD. However, the mass center of native and mutant A&#x3b2;42 was kept constant, and the complex was pulled in each direction. At a distance of 0.4&#xa0;nm, SMD ended when the bavachalcone, bavachin, and neobavaisoflavone were completely unbound from the native structure, signifying that the complexes completely dissociated these herbal compounds. Subsequently, the simulation snapshots were saved at every 10-ps interval.</p>
</sec>
<sec id="s2-6">
<title>Free Energy Landscape</title>
<p>To achieve the near-native structural conformation employing the conformational sampling process, we obtained the free energy protein landscape. At this point, DMD was performed to sample mutant and mutant-complex protein conformations. We used two critical components as reaction coordinates, viz., root-mean-square deviation (RMSD) and radius of gyration (Rg) to acquire free energy landscape. With these two components, we determined the energy landscape based on the following equation:<disp-formula id="equ1">
<mml:math id="m1">
<mml:mrow>
<mml:mi>&#x394;</mml:mi>
<mml:mtext>G</mml:mtext>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mtext>p</mml:mtext>
<mml:mn>1</mml:mn>
<mml:mo>,</mml:mo>
<mml:mtext>p</mml:mtext>
<mml:mn>2</mml:mn>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>&#x3d;</mml:mo>
<mml:mo>&#x2212;</mml:mo>
<mml:mtext>kBT</mml:mtext>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mtext>In</mml:mtext>
<mml:mtext>&#x2003;</mml:mtext>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mtext>p</mml:mtext>
<mml:mn>1</mml:mn>
<mml:mo>,</mml:mo>
<mml:mtext>p</mml:mtext>
<mml:mn>2</mml:mn>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:math>
</disp-formula>
</p>
<p>Herein, kB depicts the Boltzmann constant, while &#x2206;G denotes the Gibbs free energy of state, and T represents the temperature maintained during the of simulation. p1, p2 depicts the reaction coordinates, which is used to construct 2D landscape based on the joint probability distributions: P (p1, p2) obtained from the system (<xref ref-type="bibr" rid="B30">Papaleo et&#x20;al., 2009</xref>).</p>
</sec>
</sec>
<sec sec-type="results|discussion" id="s3">
<title>Results and Discussion</title>
<sec id="s3-1">
<title>Protein&#x2013;Ligand Binding and Interaction Analysis</title>
<p>Docking-optimized structures of both the receptor and ligand were created to identify molecules that may bind to the interested protein target (<xref ref-type="bibr" rid="B37">Sethi et&#x20;al., 2019</xref>). Molecular docking is an essential aspect in the case of structure-based drug designing. Docking strategies explore high-dimensional spaces effectively, and the scoring functions are used to rank the small-molecule candidates that are docked with the receptor protein. Moreover, the molecular docking process evaluates a protein&#x2013;receptor complex using various factors such as binding energies and intermolecular interactions that include hydrogen bonds and hydrophobic interactions (<xref ref-type="bibr" rid="B26">Meng et&#x20;al., 2011</xref>; <xref ref-type="bibr" rid="B24">Leelananda and Lindert, 2016</xref>; <xref ref-type="bibr" rid="B49">Wang and Zhu, 2016</xref>). From those mentioned above, the more potent, selective, and efficient drug candidates could be developed to treat AD. The NMR structure of A&#x3b2;42 (2BEG) from PDB is used as a protein receptor. The compounds are geometrically optimized and the water molecules are detached for performing molecular docking studies. Consequently, the herbal compounds, bavachalcone, bavachin, and neobavaisoflavone were embedded in the active site of the A&#x3b2;42 receptor as the best docked complex based on binding orientation (<xref ref-type="table" rid="T1">Table&#x20;1</xref>). Thus, the docked complex of A&#x3b2;42-bavachalcone exhibits about &#x2212;8.23&#xa0;kcal/mol binding energy, while bavachin and neobavaisoflavone exhibited &#x2212;8.10 and &#x2212;8.09&#xa0;kcal/mol binding energy, respectively. From the results, we could infer that bavachalcone has a higher binding energy comparatively than bavachin and neobavaisoflavone. During the interactions, a bavachalcone molecule forms two hydrogen bonds with residues Leu17 (chain A) and Val18 (chain C) amyloid-beta fibril. The distance of the hydrogen bond for Leu17 is 3.00&#xa0;&#xc5;, and that for Val18 is 2.86&#xa0;&#xc5;. The bavachin compound does not form a hydrogen bond with the A&#x3b2;42 receptor. A neobavaisoflavone molecule forms one hydrogen bond with residue Leu17 of chain C at a distance of 2.96&#xa0;&#xc5; (<xref ref-type="fig" rid="F3">Figure&#x20;3</xref>) (<xref ref-type="table" rid="T2">Table&#x20;2</xref>). Comparatively, neobavaisoflavone has a lower binding energy, but it forms a hydrogen bond with the receptor, which is essential in forming a stabilized protein&#x2013;ligand complex. In accordance, bavachalcone and neobavaisoflavone are considered to be more effective inhibiting complexes. However, the hydrophobic effect is essential in the arrangement of A&#x3b2;42 oligomers into stabilized A&#x3b2;42 fibrils. Thus, the hydrophobic residues demonstrate the stabilization of amyloid-beta fibril (<xref ref-type="bibr" rid="B25">Marshall et&#x20;al., 2011</xref>). Interaction of bavachalcone and neobavaisoflavone with A&#x3b2;42 fibril structure binds the hydrophobic residues Leu17, Val40, Phe19, Val18, and Ala42. Bavachin forms the hydrophobic interactions with Leu17, Val40, Phe19, and Val18&#x20;<bold>(</bold>
<xref ref-type="fig" rid="F3">Figure&#x20;3</xref>). Hydrophobic interactions of both bavachalcone and neobavaisoflavone molecules have common amino acid residues, and therefore, the selected herbal compounds have shown considerable binding energy.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Compounds utilized for the molecular docking with amyloid-beta peptide.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">No</th>
<th align="center">Compound name</th>
<th align="center">Ligand structure</th>
<th align="center">Iupac name</th>
<th align="center">Chemical formula</th>
<th align="center">Molecular weight</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">1</td>
<td align="left">Bavachalcone</td>
<td align="left">
<inline-graphic xlink:href="fchem-09-753146-fx1.tif"/>
</td>
<td align="left">(E)-1-[2,4-dihydroxy-5-(3-methylbut-2-enyl)phenyl]-3 (4hydroxyphenyl) prop-2-en-1-one</td>
<td align="left">C<sub>20</sub>H<sub>20</sub>O<sub>4</sub>
</td>
<td align="left">324.4&#xa0;g/mol</td>
</tr>
<tr>
<td align="left">2</td>
<td align="left">Bavachin</td>
<td align="left">
<inline-graphic xlink:href="fchem-09-753146-fx2.tif"/>
</td>
<td align="left">(2S)-7-hydroxy-2-(4-hydroxyphenyl)-6-(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one</td>
<td align="left">C<sub>20</sub>H<sub>20</sub>O<sub>4</sub>
</td>
<td align="left">324.4&#xa0;g/mol</td>
</tr>
<tr>
<td align="left">3</td>
<td align="left">Neobavaisoflavone</td>
<td align="left">
<inline-graphic xlink:href="fchem-09-753146-fx3.tif"/>
</td>
<td align="left">7-hydroxy-3-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]chromen-4-one</td>
<td align="left">C<sub>20</sub>H<sub>18</sub>O<sub>4</sub>
</td>
<td align="left">322.4&#xa0;g/mol</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Docking view of A&#x3b2;42 fibril structure interacting with the three best docked herbal compounds <bold>(A)</bold> bavachin, <bold>(B)</bold> bavachacone, and <bold>(C)</bold> neobavaisoflavone that forms hydrogen bond (brown) and hydrophobic residues (orange) were plotted using LIGPLOT.</p>
</caption>
<graphic xlink:href="fchem-09-753146-g003.tif"/>
</fig>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Interactions resulted from docking analysis of the compounds with amyloid-beta peptide.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Docked compound</th>
<th align="center">Binding energy (kcal/mol)</th>
<th align="center">Hydrogen bonds</th>
<th align="center">Hydrophobic interactions</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Bavachalcone</td>
<td align="char" char=".">&#x2212;8.23</td>
<td align="center">Leu17, Val18</td>
<td align="center">Leu17, Val40, Phe19, Val18, Ala42</td>
</tr>
<tr>
<td align="left">Bavachin</td>
<td align="char" char=".">&#x2212;8.10</td>
<td align="center">&#x2014;</td>
<td align="center">Leu17, Val40, Phe19, Val18</td>
</tr>
<tr>
<td align="left">Neobavaisoflavone</td>
<td align="char" char=".">&#x2212;8.09</td>
<td align="center">Leu17</td>
<td align="center">Leu17, Val40, Phe19, Val18, Ala42</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>To further investigate into the protein&#x2013;ligand associations, the prenylflavonoids complexes&#x2019; dissociation constants were calculated upon binding. Herein, epigallocatechin gallate (EGCG), an evinced anti-amyloid that showed potency at minimal concentrations of 7.5&#xa0;mg/ml (<xref ref-type="bibr" rid="B22">Lee et&#x20;al., 2009</xref>), was used as a positive control to compare the dissociation constant metrics with the prenylflavonoids being analyzed. Reaction kinetics states that the lower the dissociation constant, the higher the binding affinity between the protein and ligand (<xref ref-type="bibr" rid="B8">Corzo, 2006</xref>; <xref ref-type="bibr" rid="B12">Du et&#x20;al., 2016</xref>); accordingly, calculations show that all the three prenylflavonoids&#x2019; dissociation constants were on par with each other with slight variations, and more importantly, the values were substantially lower when compared with EGCG&#x2019;s dissociation constant upon binding with Ab42 amyloid fibril (<xref ref-type="table" rid="T3">Table&#x20;3</xref>). Findings indicate that compared to positive control EGCG, all the three prenylflavonoids evince a considerably higher interaction with Ab42 amyloid fibril. Hence, combining docking scores and dissociation constant values, bavachalcone and neobavaisoflavone reported a higher intermolecular interaction than bavachin complex, which insinuates a potential alleviation of Ab42 mediated pathology, since the higher the binding, the better the ligand pose holds on the protein (<xref ref-type="bibr" rid="B21">Kumar and Doss, 2016</xref>).</p>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>Table elucidating dissociation constant of Ab42 peptide complexed with ligands.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Ab42 complexed with ligands</th>
<th align="center">Dissociation constant (microMolar)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Bavachalcone</td>
<td align="char" char=".">0.99</td>
</tr>
<tr>
<td align="left">Bavachin</td>
<td align="char" char=".">1.14</td>
</tr>
<tr>
<td align="left">Neobavaisoflavone</td>
<td align="char" char=".">1.18</td>
</tr>
<tr>
<td align="left">EGCG</td>
<td align="char" char=".">40.19</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>To provide a detailed understanding on the structural interaction, we performed atomic-level studies on the compound structures recovered before and after docking, using the quantum mechanics tool. Conversely, findings from the QM analysis exposing the HOMO/LUMO energy gap difference of the compounds, before and after docking (<xref ref-type="table" rid="T4">Table&#x20;4</xref>), suggested that neobavaisoflavone showed a considerable variation in the energy gap in contrast to that of other compounds (<xref ref-type="fig" rid="F4">Figure&#x20;4</xref>). To further substantiate the static analysis from the molecular docking and quantum mechanics studies, we utilized discrete molecular dynamics to illustrate the association of compounds over aggregated A&#x3b2;42protein through dynamic scale within a defined system over a period of&#x20;time.</p>
<table-wrap id="T4" position="float">
<label>TABLE 4</label>
<caption>
<p>HOMO/LUMO energy gap of the compounds before and after docking.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th rowspan="2" align="left">Compounds</th>
<th colspan="2" align="center">HOMO-LUMO energy gap (eV)</th>
<th rowspan="2" align="center">EnergyDifference (eV)</th>
</tr>
<tr>
<th align="center">Before docking</th>
<th align="center">After docking</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Bavachalcone</td>
<td align="center">4.052</td>
<td align="center">4.291</td>
<td align="char" char=".">&#x2212;0.239</td>
</tr>
<tr>
<td align="left">Bavachin</td>
<td align="center">4.766</td>
<td align="center">4.665</td>
<td align="char" char=".">0.111</td>
</tr>
<tr>
<td align="left">Neobavaisoflavone</td>
<td align="center">4.19</td>
<td align="center">3.866</td>
<td align="char" char=".">0.324</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Quantum mechanics on all the compounds before and after docking were calculared. The HOMO (red/blue), LUMO (brown/yellow), and electrostatic potential were computed using Def-SVP basis set with B3-LYP function in which Neobavaisoflavonealone exhibited greater change in the energy gap between the apo and docked complex&#x20;state.</p>
</caption>
<graphic xlink:href="fchem-09-753146-g004.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>Discrete Molecular Dynamic Simulations Protein&#x2013;Ligand Complex and Native</title>
<p>Subsequently, we simulated the above-mentioned docked compounds for 1&#x20;&#xd7; 10<sup>5</sup> time units, wherein root mean square deviation (RMSD) was measured by plotting RMSD versus time. In native simulations, RMSD values are rising rapidly and attain the stability at 0.8 nm; the protein&#x2013;ligand complex showed fluctuations, stabilized at approximately 1.2&#xa0;nm, and then, it was rather steady during the rest of simulation. Thus, the protein&#x2013;ligand complex was found to stabilize during the simulation (<xref ref-type="bibr" rid="B18">Kato et&#x20;al., 2017</xref>). Based on the molecular simulation, RMSD values of bavachalcone, bavachin, and neobavaisoflavone bound to A&#x3b2;42 fibril were stabilized between 0.5 and 1&#xa0;nm, thereby maintaining the flexibility and compactness. There were no fluctuations found in protein&#x2013;ligand complexes, while the native amyloid fibril showed a more significant deviation at a range of 1&#x2013;1.3&#xa0;nm (<xref ref-type="fig" rid="F5">Figure&#x20;5</xref>). Correspondingly, these three compounds exhibited stronger binding to A&#x3b2;42 fibril, due to the compact and stable structure.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>RMSD graph for protein&#x2013;ligand complex from Discrete molecular dynamics.</p>
</caption>
<graphic xlink:href="fchem-09-753146-g005.tif"/>
</fig>
<p>Subsequently, the protein&#x2013;ligand complex stability was further analyzed, using Rg. Amyloid fibril native displayed a Rg value of approximately 1.5&#xa0;nm; the fluctuation decreased with time and formed a stable structure at 1.55&#xa0;nm, whereas both bavachalcone and bavachin complex displayed a Rg value of 1.6&#xa0;nm that decreased with time and stabilized at 1.49 and 1.35&#xa0;nm, thereby exhibiting a greater difference in their compactness with A&#x3b2;42 fibril, respectively. However, neobavaisoflavone bound with A&#x3b2;42 fibril with a Rg value of 1.5&#xa0;nm, which further decreased and stabilized at approximately 1.44&#xa0;nm (<xref ref-type="fig" rid="F6">Figure&#x20;6</xref>), during the complete course of simulation. In comparison to the Rg value of native A&#x3b2;42 fibril, the protein&#x2013;ligand complexes displayed the lowest Rg that was stabilized, thus suggesting the lower Rg value resulting in tight bonding of the resultant complex. Thus, in the course of the simulation, A&#x3b2;42 binding with bavachalcone, bavachin, and neobavaisoflavone complex was found to be more compact and stable. Furthermore, RMSF analysis was further evaluated to determine the stability and flexibility of the complexes, where the fluctuations were observed, during the process of bavachalcone, bavachin, and neobavaisoflavone binding to the surface of A&#x3b2;42 fibril (<xref ref-type="fig" rid="F7">Figure&#x20;7</xref>). RMSF values validate that neobavaisoflavone was more effective in binding to the hydrophobic core of A&#x3b2;42 compared to bavachalcone and bavachin. Thus, the interaction of A&#x3b2;42 fibril with bavachalcone, bavachin, and neobavaisoflavone complexes demonstrated the inhibitory effects to destabilize the fibril structure and prevent plaque formation. From the herbal compounds, we examined that due to the loss of hydrogen bond interaction, bavachin is not found to be impressive. Resultantly, neobavaisoflavone is found to be more effective in inhibitory actions, thereby showing a stronger</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Radius of gyration graph for protein&#x2013;ligand complex from Discrete molecular dynamics.</p>
</caption>
<graphic xlink:href="fchem-09-753146-g006.tif"/>
</fig>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Root mean square fluctuation graph for protein&#x2013;ligand complex from Discrete molecular dynamics.</p>
</caption>
<graphic xlink:href="fchem-09-753146-g007.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>SMD Evaluation</title>
<p>To understand the molecular structure of a compound, the association properties such as hydrogen bonds, hydrophobic residues, and the dissociation properties are essential. Steered molecular dynamics plays a vital role in the field of drug designing to measure its stability and in studying the relationship between the protein&#x2013;ligand complex (<xref ref-type="bibr" rid="B11">Do et&#x20;al., 2018</xref>). The protein&#x2013;ligand complex that unbinds increase in time (picoseconds) has strong binding, which is found to be a more stable complex. Thus, results from the SMD simulations showed the time required to disassociate bavachalcone (60 ps), bavachin (30 ps), and neobavaisoflavone (130 ps) from A&#x3b2;42 fibril (<xref ref-type="fig" rid="F8">Figure&#x20;8</xref>). Based on the results, we could clearly infer that neobavaisoflavone has greater binding strength and stability in contrast to that of bavachalcone and bavachin.</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>SMD was performed to measure the unbinding period of compounds bavachalcone (blue), bavachin (green), and neobavaisoflavone (red) that are bound to A&#x3b2;42 fibril.</p>
</caption>
<graphic xlink:href="fchem-09-753146-g008.tif"/>
</fig>
<p>Furthermore, the binding efficacy of aforementioned polyphenols was compared with the metrics of proven potent anti-amyloid EGCG, which has exhibited considerable binding and anti-aggregate proclivities against A&#x3b2;42 fibril aggregates (<xref ref-type="bibr" rid="B34">Rezai-Zadeh et&#x20;al., 2005</xref>; <xref ref-type="bibr" rid="B31">Park et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B52">Zhang et&#x20;al., 2020</xref>). The higher the time taken during SMD, the higher the binding efficacy between the protein and ligand. Accordingly, the positive control EGCG evinced 50 ps to completely dissociate from amyloid A&#x3b2;42, which is comparable to that of bavachalcone and a bit more when compared with bavachin. However, SMD values of neobavaisoflavone is considerably higher when compared to EGCG, which indicates that the former shows notable interaction with the amyloid, which is significantly higher than the well-established positive control EGCG&#x2019;s interaction with the same. Thus, the docking studies and the SMD simulations altogether conclude that neobavaisoflavone is found to be more stable as compared to that of other compounds, which narrowed down our study towards further analysis.</p>
</sec>
<sec id="s3-4">
<title>Secondary Structure Studies</title>
<p>Interactions between the polypeptide chains containing the alpha-helix and beta-pleated sheets evince a crucial part in the formation of a secondary structural framework in a protein. H-bond formation among the residues leads to the evolution of alpha-helix and beta-pleated sheets. Therefore, secondary structure properties such as &#x3b2;-sheets, coil, turn, helix, and others are evaluated, which supports this study. Accordingly, the percentage of secondary structure values for bavachalcone, bavachin, and neobavaisoflavone of coil, turn, &#x3b2;-bridge, and alpha-helix was found to be increased in comparison to native (<xref ref-type="table" rid="T5">Table&#x20;5</xref>). From the overall results, neobavaisoflavone has drastic reduction in &#x3b2;-sheet propensity, with the increase in turns, coils, and helix indicating the degrading ability of the compound and preventing the formation of &#x3b2;-strands, followed by the formation of amyloid aggregates.</p>
<table-wrap id="T5" position="float">
<label>TABLE 5</label>
<caption>
<p>Comparison of A&#x3b2;42 (native) secondary structure against bavachalcone, bavachin, and neobavaisoflavone using the DSSP program.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Secondary structure elements</th>
<th align="center">Native</th>
<th align="center">Bavachalcone</th>
<th align="center">Bavachin</th>
<th align="center">Neobavaisoflavone</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Structure</td>
<td align="char" char=".">53</td>
<td align="char" char=".">40</td>
<td align="char" char=".">44</td>
<td align="char" char=".">35</td>
</tr>
<tr>
<td align="left">Coil</td>
<td align="char" char=".">32</td>
<td align="char" char=".">43</td>
<td align="char" char=".">40</td>
<td align="char" char=".">47</td>
</tr>
<tr>
<td align="left">&#x3b2;-Sheet</td>
<td align="char" char=".">42</td>
<td align="char" char=".">27</td>
<td align="char" char=".">29</td>
<td align="char" char=".">17</td>
</tr>
<tr>
<td align="left">&#x3b2;-Bridge</td>
<td align="char" char=".">4</td>
<td align="char" char=".">4</td>
<td align="char" char=".">5</td>
<td align="char" char=".">7</td>
</tr>
<tr>
<td align="left">Bend</td>
<td align="char" char=".">12</td>
<td align="char" char=".">14</td>
<td align="char" char=".">11</td>
<td align="char" char=".">14</td>
</tr>
<tr>
<td align="left">Turn</td>
<td align="char" char=".">7</td>
<td align="char" char=".">7</td>
<td align="char" char=".">8</td>
<td align="char" char=".">8</td>
</tr>
<tr>
<td align="left">Alpha-Helix</td>
<td align="char" char=".">0</td>
<td align="char" char=".">2</td>
<td align="char" char=".">2</td>
<td align="char" char=".">2</td>
</tr>
<tr>
<td align="left">3-Helix</td>
<td align="char" char=".">0</td>
<td align="char" char=".">0</td>
<td align="char" char=".">2</td>
<td align="char" char=".">0</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3-5">
<title>FEL Analysis</title>
<p>Free energy landscape (FEL) was evaluated to analyze the structural changes that support our study for understanding the destabilization of A&#x3b2;42 fibril. FEL represents the total number of interactions between residues and the number of interactions that correspond to the most stable native structure. Furthermore, the free energy landscape for the protein&#x2013;ligand complex exhibited varying Gibbs free energy in between the range of 1&#x2013;10&#xa0;kcal/mol. Amyloid fibrils are typically polymorphic in nature, which is one of the chief characteristics of amyloids (<xref ref-type="bibr" rid="B48">Tycko, 2015</xref>; <xref ref-type="bibr" rid="B6">Close et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B13">F&#xe4;ndrich et&#x20;al., 2018</xref>), and to further explore the pathogenic aspects of amyloid from this perspective, FEL was construed. We determined the FEL of A&#x3b2;42 fibril and its complex herbal compounds such as bavachalcone, bavachin, and neobavaisoflavone by utilizing the RMSD and Rg coordinates (<xref ref-type="fig" rid="F9">Figure&#x20;9</xref>). The FEL for unbound A&#x3b2;42 fibril resulted in multiple free energy basins that are located within the Rg value of 1.47&#xa0;nm and RMSD value of 0.3&#xa0;nm, respectively. An increase in the development of multiple free energy basins indicates an increase in the formation of fibril structures that bind together and produce senile plaques (<xref ref-type="bibr" rid="B51">Wang et&#x20;al., 2014</xref>). Bavachalcone bound to A&#x3b2;42 fibril forms two basins with Rg and RMSD values of 1.44&#x2013;1.46&#xa0;nm and 0.25&#x2013;0.3&#xa0;nm, respectively, whereas bavachin binding A&#x3b2;42 fibril forms three free energy basins between 1.3 and 1.4&#xa0;nm Rg values and about 0.3&#xa0;nm RMSD value. In contrast to free energy values of the above-mentioned compounds, neobavaisoflavone produced only one confirmative basin within a Rg value of 1.4&#xa0;nm and a RMSD value of 0.3 nm, implying a conformational restriction by the polyphenol over A&#x3b2;42. A decrease in the number of free energy basins represents an increase in the inhibitory effect of the herbal compound. Though the compounds bavachalcone and bavachin have a reduction in the number of basins, neobavaisoflavone has the least number of only one basin, which is found to be more efficient comparatively. Therefore, the overall results obtained from molecular docking, molecular dynamics simulations, steered molecular dynamics, secondary structure analysis, and FEL analysis exposed that neobavaisoflavone has considerable binding strength with A&#x3b2;42 fibril and the ability to destabilize fibril formation, compared to bavachalcone and bavachin. Based on this study, the prenylflavonoid neobavaisoflavone could act as a potent therapeutic compound in advancing anti-Alzheimer&#x2019;s drug development.</p>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption>
<p>Free energy landscape presents the view of A&#x3b2;42 aggregates and A&#x3b2;42 aggregates obstructed by binding to bavachalcone, bavachin, and neobavaisoflavone. The study resulted in the compound neobavaisoflavone being quite efficient in inhibiting the formation of A&#x3b2;42 aggregates.</p>
</caption>
<graphic xlink:href="fchem-09-753146-g009.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="conclusion" id="s4">
<title>Conclusion</title>
<p>Therapeutic agents for various diseases flooded in nature are still unidentified. Comparatively, the natural compounds are safe and show a reduced level of side effects than the chemical compound-based drug discovery. Therefore, the researchers take their steps in search of natural compounds for curative therapies. In recent years, the herbal compounds have been an essential component in AD treatment, wherein the mechanism of inhibition depends on the aromatic and hydrophobic association between the misfolded protein aggregate and the small-molecule inhibitors. Reduction in the accumulation of misfolded A&#x3b2;42 structures by stabilizing the native conformation can be used in the prevention of amyloid-beta aggregation. <italic>In silico</italic> approach of structure-based drug discovery can be used to identify herbal compounds that target amyloid-beta 42 aggregates. According to the docking results, bavachalcone, bavachin, and neobavaisoflavone have been identified as potent inhibitors with the highest binding affinity among the docked compounds along with the control EGCG. SMD and QM results reinforced neobavaisoflavone for exhibiting a strong binding effect compared to other compounds. Besides, the formation of a single free energy basin resulting from free energy landscape showed that neobavaisoflavone has a greater stability and abides by the properties of the drug compared to bavachalcone and bavachin. This approach is used for the identification of potent and specific drug lead compounds that break A&#x3b2;42&#x20;&#x3b2;-sheets using small molecules, thereby inhibiting and reversing A&#x3b2;42 misfolding and oligomerization activity. Hence, developing a structure-based drug design using the pharmacophore of naturally available prenylflavonoids could play a significant role in AD treatment.</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Data Availability Statement</title>
<p>The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s6">
<title>Author Contributions</title>
<p>ES performed research work, analyzed and drafted the manuscript. GC and PC helped in drafting the manuscript. KA, AV, IT, and RK corrected the proof of the manuscript. RR conceptualized the research and oversaw the manuscript.</p>
</sec>
<sec sec-type="COI-statement" id="s7">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s8">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ack>
<p>We express gratitude to the management of VIT (Deemed to&#x20;be University) for granting VIT SEED GRANT (VIT/SG/2020-21/43) and the system facilities. ES expresses gratitude&#x20;to CSIR for granting Senior Research Fellowship to perform this research work. ES, KA, and ASA thank the management of Saveetha School of Engineering, SIMATS. RK thanks the management of AIMST University for the support.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Ayadhi</surname>
<given-names>L. Y.</given-names>
</name>
<name>
<surname>Ben Bacha</surname>
<given-names>A. G.</given-names>
</name>
<name>
<surname>Kotb</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>El-Ansary</surname>
<given-names>A. K.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>A Novel Study on Amyloid &#x3b2; Peptide 40, 42 and 40/42 Ratio in Saudi Autistics</article-title>. <source>Behav. Brain Funct.</source> <volume>8</volume>, <fpage>4</fpage>. <pub-id pub-id-type="doi">10.1186/1744-9081-8-4</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bilan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Freyssin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Page</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fauconneau</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Natural Polyphenols Effects on Protein Aggregates in Alzheimer&#x27;s and Parkinson&#x27;s Prion-like Diseases</article-title>. <source>Neural Regen. Res.</source> <volume>13</volume>, <fpage>955</fpage>. <pub-id pub-id-type="doi">10.4103/1673-5374.233432</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bulfone</surname>
<given-names>T. C.</given-names>
</name>
<name>
<surname>Samuel</surname>
<given-names>S. P.</given-names>
</name>
<name>
<surname>Bickler</surname>
<given-names>P. E.</given-names>
</name>
<name>
<surname>Lewin</surname>
<given-names>M. R.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Developing Small Molecule Therapeutics for the Initial and Adjunctive Treatment of Snakebite</article-title>. <source>J.&#x20;Trop. Med.</source> <volume>2018</volume>, <fpage>1</fpage>&#x2013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1155/2018/4320175</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>G.-F.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>T.-H.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.-R.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Melcher</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development</article-title>. <source>Acta Pharmacol. Sin.</source> <volume>38</volume>, <fpage>1205</fpage>&#x2013;<lpage>1235</lpage>. <pub-id pub-id-type="doi">10.1038/aps.2017.28</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ciechanover</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>Y. T.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Degradation of Misfolded Proteins in Neurodegenerative Diseases: Therapeutic Targets and Strategies</article-title>. <source>Exp. Mol. Med.</source> <volume>47</volume>, <fpage>e147</fpage>. <pub-id pub-id-type="doi">10.1038/emm.2014.117</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Close</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hora</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Annamalai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Physical Basis of Amyloid Fibril Polymorphism</article-title>. <source>Nat. Commun.</source> <volume>9</volume>, <fpage>699</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-018-03164-5</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colvin</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Silvers</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Frohm</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Linse</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Griffin</surname>
<given-names>R. G.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>High Resolution Structural Characterization of A&#x3b2;42 Amyloid Fibrils by Magic Angle Spinning NMR</article-title>. <source>J.&#x20;Am. Chem. Soc.</source> <volume>137</volume>, <fpage>7509</fpage>&#x2013;<lpage>7518</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.5b03997</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corzo</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Time, the Forgotten Dimension of Ligand Binding Teaching</article-title>. <source>Biochem. Mol. Biol. Educ.</source> <volume>34</volume>, <fpage>413</fpage>&#x2013;<lpage>416</lpage>. <pub-id pub-id-type="doi">10.1002/bmb.2006.494034062678</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Darden</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>York</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>Particle Mesh Ewald: AnN&#x22c5;Log(N) Method for Ewald Sums in Large Systems</article-title>. <source>J.&#x20;Chem. Phys.</source> <volume>98</volume>, <fpage>10089</fpage>&#x2013;<lpage>10092</lpage>. <pub-id pub-id-type="doi">10.1063/1.464397</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ding</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Dokholyan</surname>
<given-names>N. V.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Dynamical Roles of Metal Ions and the Disulfide Bond in Cu, Zn Superoxide Dismutase Folding and Aggregation</article-title>. <source>Proc. Natl. Acad. Sci.</source> <volume>105</volume>, <fpage>19696</fpage>&#x2013;<lpage>19701</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0803266105</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Do</surname>
<given-names>P.-C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>E. H.</given-names>
</name>
<name>
<surname>Le</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Steered Molecular Dynamics Simulation in Rational Drug Design</article-title>. <source>J.&#x20;Chem. Inf. Model.</source> <volume>58</volume>, <fpage>1473</fpage>&#x2013;<lpage>1482</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.8b00261</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>Y.-L.</given-names>
</name>
<name>
<surname>Ai</surname>
<given-names>S.-M.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sang</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Insights into Protein-Ligand Interactions: Mechanisms, Models, and Methods</article-title>. <source>Ijms</source> <volume>17</volume>, <fpage>144</fpage>. <pub-id pub-id-type="doi">10.3390/ijms17020144</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>F&#xe4;ndrich</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nystr&#xf6;m</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>K. P. R.</given-names>
</name>
<name>
<surname>B&#xf6;ckmann</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>LeVine</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hammarstr&#xf6;m</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Amyloid Fibril Polymorphism: a challenge for Molecular Imaging and Therapy</article-title>. <source>J.&#x20;Intern. Med.</source> <volume>283</volume>, <fpage>218</fpage>&#x2013;<lpage>237</lpage>. <pub-id pub-id-type="doi">10.1111/joim.12732</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finder</surname>
<given-names>V. H.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Alzheimer&#x27;s Disease: A General Introduction and Pathomechanism</article-title>. <source>JAD</source> <volume>22</volume>, <fpage>S5</fpage>&#x2013;<lpage>S19</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-2010-100975</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gouras</surname>
<given-names>G. K.</given-names>
</name>
<name>
<surname>Olsson</surname>
<given-names>T. T.</given-names>
</name>
<name>
<surname>Hansson</surname>
<given-names>O.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>&#x3b2;-Amyloid Peptides and Amyloid Plaques in Alzheimer&#x27;s Disease</article-title>. <source>Neurotherapeutics</source> <volume>12</volume>, <fpage>3</fpage>&#x2013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1007/s13311-014-0313-y</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Gurevich</surname>
<given-names>E. V.</given-names>
</name>
<name>
<surname>Gurevich</surname>
<given-names>V. V.</given-names>
</name>
</person-group> (<year>2014</year>). &#x201c;<article-title>Therapeutic Potential of Small Molecules and Engineered Proteins</article-title>,&#x201d; in <source>Arrestins - Pharmacology and Therapeutic Potential</source>. Editor <person-group person-group-type="editor">
<name>
<surname>Gurevich</surname>
<given-names>V. V.</given-names>
</name>
</person-group> (<publisher-loc>Berlin, Heidelberg</publisher-loc>: <publisher-name>Springer Berlin Heidelberg</publisher-name>), <fpage>1</fpage>&#x2013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-642-41199-1_1</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hess</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kutzner</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>van der Spoel</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lindahl</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation</article-title>. <source>J.&#x20;Chem. Theor. Comput.</source> <volume>4</volume>, <fpage>435</fpage>&#x2013;<lpage>447</lpage>. <pub-id pub-id-type="doi">10.1021/ct700301q</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kato</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nakayoshi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fukuyoshi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kurimoto</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Oda</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Validation of Molecular Dynamics Simulations for Prediction of Three-Dimensional Structures of Small Proteins</article-title>. <source>Molecules</source> <volume>22</volume>, <fpage>1716</fpage>. <pub-id pub-id-type="doi">10.3390/molecules22101716</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Thiessen</surname>
<given-names>P. A.</given-names>
</name>
<name>
<surname>Bolton</surname>
<given-names>E. E.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gindulyte</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2016a</year>). <article-title>PubChem Substance and Compound Databases</article-title>. <source>Nucleic Acids Res.</source> <volume>44</volume>, <fpage>D1202</fpage>&#x2013;<lpage>D1213</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkv951</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>H.-S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>S.-J.</given-names>
</name>
</person-group> (<year>2016b</year>). <article-title>Quantitative Analysis of Psoralea Corylifolia Linne and its Neuroprotective and Anti-neuroinflammatory Effects in HT22 Hippocampal Cells and BV-2 Microglia</article-title>. <source>Molecules</source> <volume>21</volume>, <fpage>1076</fpage>. <pub-id pub-id-type="doi">10.3390/molecules21081076</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>D. T.</given-names>
</name>
<name>
<surname>GeorgePriyaDoss</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Investigating the Inhibitory Effect of Wortmannin in the Hotspot Mutation at Codon 1047 of PIK3CA Kinase Domain</article-title>. <source>Adv. Protein Chem. Struct. Biol.</source> <volume>102</volume>, <fpage>267</fpage>&#x2013;<lpage>297</lpage>. <pub-id pub-id-type="doi">10.1016/bs.apcsb.2015.09.008</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>J.&#x20;W.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y. K.</given-names>
</name>
<name>
<surname>Ban</surname>
<given-names>J.&#x20;O.</given-names>
</name>
<name>
<surname>Ha</surname>
<given-names>T. Y.</given-names>
</name>
<name>
<surname>Yun</surname>
<given-names>Y. P.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>S. B.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>Green Tea (-)-Epigallocatechin-3-Gallate Inhibits &#x3b2;-Amyloid-Induced Cognitive Dysfunction through Modification of Secretase Activity via Inhibition of ERK and NF-&#x39a;b Pathways in Mice</article-title>. <source>J.&#x20;Nutr.</source> <volume>139</volume>, <fpage>1987</fpage>&#x2013;<lpage>1993</lpage>. <pub-id pub-id-type="doi">10.3945/jn.109.109785</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jun</surname>
<given-names>H.-S.</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>Y. S.</given-names>
</name>
</person-group> (<year>20162016</year>). <article-title>Protective Effect of <italic>Psoralea Corylifolia</italic> L. Seed Extract against Palmitate-Induced Neuronal Apoptosis in PC12 Cells</article-title>. <source>Evidence-Based Complement. Altern. Med.</source> <volume>2016</volume>, <fpage>1</fpage>&#x2013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1155/2016/5410419</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leelananda</surname>
<given-names>S. P.</given-names>
</name>
<name>
<surname>Lindert</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Computational Methods in Drug Discovery</article-title>. <source>Beilstein J.&#x20;Org. Chem.</source> <volume>12</volume>, <fpage>2694</fpage>&#x2013;<lpage>2718</lpage>. <pub-id pub-id-type="doi">10.3762/bjoc.12.267</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marshall</surname>
<given-names>K. E.</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>K. L.</given-names>
</name>
<name>
<surname>Charlton</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>O&#x2019;Reilly</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Walden</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Hydrophobic, Aromatic, and Electrostatic Interactions Play a Central Role in Amyloid Fibril Formation and Stability</article-title>. <source>Biochemistry</source> <volume>50</volume>, <fpage>2061</fpage>&#x2013;<lpage>2071</lpage>. <pub-id pub-id-type="doi">10.1021/bi101936c</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meng</surname>
<given-names>X.-Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.-X.</given-names>
</name>
<name>
<surname>Mezei</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Molecular Docking: a Powerful Approach for Structure-Based Drug Discovery</article-title>. <source>Cad</source> <volume>7</volume>, <fpage>146</fpage>&#x2013;<lpage>157</lpage>. <pub-id pub-id-type="doi">10.2174/157340911795677602</pub-id> </citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morris</surname>
<given-names>G. M.</given-names>
</name>
<name>
<surname>Huey</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lindstrom</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Sanner</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>Belew</surname>
<given-names>R.-K.</given-names>
</name>
<name>
<surname>Goodsell</surname>
<given-names>D. S.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility</article-title>. <source>J Comput Chem.</source> <volume>30(16)</volume>, <fpage>2785</fpage>&#x2013;<lpage>2791</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.21256</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murphy</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>LeVine</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Alzheimer&#x27;s Disease and the Amyloid-&#x3b2; Peptide</article-title>. <source>Jad</source> <volume>19</volume>, <fpage>311</fpage>&#x2013;<lpage>323</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-2010-1221</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Obregon</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Giunta</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Darlington</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Soluble Amyloid Precursor Protein-&#x3b1; Modulates &#x3b2;-secretase Activity and Amyloid-&#x3b2; Generation</article-title>. <source>Nat. Commun.</source> <volume>3</volume>, <fpage>777</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms1781</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Owen</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>James</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>J.&#x20;A.</given-names>
</name>
<name>
<surname>Williamson</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Goate</surname>
<given-names>A. M.</given-names>
</name>
</person-group> (<year>1990</year>). <article-title>Physical Mapping Around the Alzheimer Disease Locus on the Proximal Long Arm of Chromosome 21</article-title>. <source>Am. J.&#x20;Hum. Genet.</source> <volume>46</volume>, <fpage>316</fpage>&#x2013;<lpage>322</lpage>. </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papaleo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mereghetti</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Fantucci</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Grandori</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>De Gioia</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Free-energy Landscape, Principal Component Analysis, and Structural Clustering to Identify Representative Conformations from Molecular Dynamics Simulations: The Myoglobin Case</article-title>. <source>J.&#x20;Mol. Graphics Model.</source> <volume>27</volume>, <fpage>889</fpage>&#x2013;<lpage>899</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmgm.2009.01.006</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Distinguishing the Effect on the Rate and Yield of A&#x3b2;42 Aggregation by Green Tea Polyphenol EGCG</article-title>. <source>ACS Omega</source> <volume>5</volume>, <fpage>21497</fpage>&#x2013;<lpage>21505</lpage>. <pub-id pub-id-type="doi">10.1021/acsomega.0c02063</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pimplikar</surname>
<given-names>S. W.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Reassessing the Amyloid cascade Hypothesis of Alzheimer&#x27;s Disease</article-title>. <source>Int. J.&#x20;Biochem. Cell Biol.</source> <volume>41</volume>, <fpage>1261</fpage>&#x2013;<lpage>1268</lpage>. <pub-id pub-id-type="doi">10.1016/j.biocel.2008.12.015</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reitz</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>20122012</year>). <article-title>Alzheimer&#x27;s Disease and the Amyloid Cascade Hypothesis: A Critical Review</article-title>. <source>Int. J.&#x20;Alzheimer&#x27;s Dis.</source> <volume>2012</volume>, <fpage>1</fpage>&#x2013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1155/2012/369808</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rezai-Zadeh</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Shytle</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jeanniton</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Green tea Epigallocatechin-3-Gallate (EGCG) Modulates Amyloid Precursor Protein Cleavage and Reduces Cerebral Amyloidosis in Alzheimer Transgenic Mice</article-title>. <source>J.&#x20;Neurosci.</source> <volume>25</volume>, <fpage>8807</fpage>&#x2013;<lpage>8814</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1521-05.2005</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ricciarelli</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fedele</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>The Amyloid Cascade Hypothesis in Alzheimer&#x27;s Disease: It&#x27;s Time to Change Our Mind</article-title>. <source>Cn</source> <volume>15</volume>, <fpage>926</fpage>&#x2013;<lpage>935</lpage>. <pub-id pub-id-type="doi">10.2174/1570159X15666170116143743</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarasa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sorribas</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Terrado</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Climent</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Palacios</surname>
<given-names>J.&#x20;M.</given-names>
</name>
<name>
<surname>Mengod</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Alzheimer &#x3b2;-amyloid Precursor Proteins Display Specific Patterns of Expression during Embryogenesis</article-title>. <source>Mech. Dev.</source> <volume>94</volume>, <fpage>233</fpage>&#x2013;<lpage>236</lpage>. <pub-id pub-id-type="doi">10.1016/S0925-4773(00)00297-5</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Sethi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Joshi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sasikala</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Alvala</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2019</year>). &#x201c;<article-title>Molecular Docking in Modern Drug Discovery: Principles and Recent Applications</article-title>,&#x201d; in <source>Drug Discovery and Development - New Advances [Working Title] (IntechOpen)</source>. (<publisher-loc>London, UK</publisher-loc>: <publisher-name>IntechOpen</publisher-name>)<pub-id pub-id-type="doi">10.5772/intechopen.85991</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shewmaker</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>McGlinchey</surname>
<given-names>R. P.</given-names>
</name>
<name>
<surname>Wickner</surname>
<given-names>R. B.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Structural Insights into Functional and Pathological Amyloid</article-title>. <source>J.&#x20;Biol. Chem.</source> <volume>286</volume>, <fpage>16533</fpage>&#x2013;<lpage>16540</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.R111.227108</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shirvanyants</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tsao</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ramachandran</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dokholyan</surname>
<given-names>N. V.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Discrete Molecular Dynamics: An Efficient and Versatile Simulation Method for Fine Protein Characterization</article-title>. <source>J.&#x20;Phys. Chem. B</source> <volume>116</volume>, <fpage>8375</fpage>&#x2013;<lpage>8382</lpage>. <pub-id pub-id-type="doi">10.1021/jp2114576</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srinivasan</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rajasekaran</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2018a</year>). <article-title>Comparative Binding of Kaempferol and Kaempferide on Inhibiting the Aggregate Formation of Mutant (G85R) SOD1 Protein in Familial Amyotrophic Lateral Sclerosis: A Quantum Chemical and Molecular Mechanics Study</article-title>. <source>BioFactors</source> <volume>44</volume>, <fpage>431</fpage>&#x2013;<lpage>442</lpage>. <pub-id pub-id-type="doi">10.1002/biof.1441</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srinivasan</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rajasekaran</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Computational Investigation of Curcumin, a Natural Polyphenol that Inhibits the Destabilization and the Aggregation of Human SOD1 Mutant (Ala4Val)</article-title>. <source>RSC Adv.</source> <volume>6</volume>, <fpage>102744</fpage>&#x2013;<lpage>102753</lpage>. <pub-id pub-id-type="doi">10.1039/C6RA21927F</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srinivasan</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rajasekaran</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Molecular Binding Response of Naringin and Naringenin to H46R Mutant SOD1 Protein in Combating Protein Aggregation Using Density Functional Theory and Discrete Molecular Dynamics</article-title>. <source>Prog. Biophys. Mol. Biol.</source> <volume>145</volume>, <fpage>40</fpage>&#x2013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbiomolbio.2018.12.003</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srinivasan</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rajasekaran</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Probing the Inhibitory Activity of Epigallocatechin-Gallate on Toxic Aggregates of Mutant (L84F) SOD1 Protein through Geometry Based Sampling and Steered Molecular Dynamics</article-title>. <source>J.&#x20;Mol. Graphics Model.</source> <volume>74</volume>, <fpage>288</fpage>&#x2013;<lpage>295</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmgm.2017.04.019</pub-id> </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srinivasan</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rajasekaran</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2018b</year>). <article-title>Quantum Chemical and Molecular Mechanics Studies on the Assessment of Interactions between Resveratrol and Mutant SOD1 (G93A) Protein</article-title>. <source>J.&#x20;Comput. Aided Mol. Des.</source> <volume>32</volume>, <fpage>1347</fpage>&#x2013;<lpage>1361</lpage>. <pub-id pub-id-type="doi">10.1007/s10822-018-0175-1</pub-id> </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srinivasan</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ravikumar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Venkataramanan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Purohit</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rajasekaran</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Molecular Mechanics and Quantum Chemical Calculations Unveil the Combating Effect of Baicalein on Human Islet Amyloid Polypeptide Aggregates</article-title>. <source>Mol. Simulation</source> <volume>45</volume>, <fpage>1538</fpage>&#x2013;<lpage>1548</lpage>. <pub-id pub-id-type="doi">10.1080/08927022.2019.1660778</pub-id> </citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steffen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Huniar</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Hellweg</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rubner</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Schroer</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>TmoleX-A Graphical User Interface for TURBOMOLE</article-title>. <source>J.&#x20;Comput. Chem.</source> <volume>31</volume>, <fpage>2067</fpage>&#x2013;<lpage>2970</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.21576</pub-id> </citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sweeney</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Baumann</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dunlop</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Frydman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kopito</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Protein Misfolding in Neurodegenerative Diseases: Implications and Strategies</article-title>. <source>Transl Neurodegener</source> <volume>6</volume>, <fpage>6</fpage>. <pub-id pub-id-type="doi">10.1186/s40035-017-0077-5</pub-id> </citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tycko</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Amyloid Polymorphism: Structural Basis and Neurobiological Relevance</article-title>. <source>Neuron</source> <volume>86</volume>, <fpage>632</fpage>&#x2013;<lpage>645</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2015.03.017</pub-id> </citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Molecular Docking for Drug Discovery and Development: a Widely Used Approach but Far from Perfect</article-title>. <source>Future Med. Chem.</source> <volume>8</volume>, <fpage>1707</fpage>&#x2013;<lpage>1710</lpage>. <pub-id pub-id-type="doi">10.4155/fmc-2016-0143</pub-id> </citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Caldwell</surname>
<given-names>J.&#x20;W.</given-names>
</name>
<name>
<surname>Kollman</surname>
<given-names>P. A.</given-names>
</name>
<name>
<surname>Case</surname>
<given-names>D. A.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Development and Testing of a General Amber Force Field</article-title>. <source>J.&#x20;Comput. Chem.</source> <volume>25</volume>, <fpage>1157</fpage>&#x2013;<lpage>1174</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.20035</pub-id> </citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jiao</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Exploring the Influence of EGCG on the &#x3b2;-Sheet-Rich Oligomers of Human Islet Amyloid Polypeptide (hIAPP1-37) and Identifying its Possible Binding Sites from Molecular Dynamics Simulation</article-title>. <source>PLoS ONE</source> <volume>9</volume>, <fpage>e94796</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0094796</pub-id> </citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.-Y.</given-names>
</name>
<name>
<surname>OuYang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J.-H.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The Pharmacological Activity of Epigallocatechin-3-Gallate (EGCG) on Alzheimer&#x27;s Disease Animal Model: A Systematic Review</article-title>. <source>Phytomedicine</source> <volume>79</volume>, <fpage>153316</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2020.153316</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>